Effect of Folic Acid and Vitaminon Pemetrexed Antifolate Chemotherapy in Nutrient Lung Cancer Cells
Authors:
Open Access
- 1 January 2013
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-10
Abstract
Pemetrexed (MTA) is a multitargeted antifolate drug approved for lung cancer therapy. Clinically, supplementation with high doses of folic acid (FA) and vitamin B12(VB12) lowers MTA cytotoxicities. An antagonistic effect of FA/VB12 on MTA efficacy has been proposed. However, patients who receive FA/VB12 show better tolerance to MTA with improved survival. The aims of this study are to investigate the modulation of FA and VB12 on MTA drug efficacy in human nonsmall cell lung cancer (NSCLC) cell lines. The sensitivities of cells, apoptosis, and MTA-regulated proteins were characterized to determine the possible effects of high doses of FA and VB12 on MTA efficacy. MTA has the lowest efficacy under 10% serum conditions. However, supplementation with FA and VB12 individually and additively reversed the insensitivity of NSCLC cells to MTA treatment with 10% serum. The enhanced sensitivities of cells following FA/VB12 treatment were correlated with increasing apoptosis and were specific to MTA but not to 5-fluorouracil (5-FU). Enhanced sensitivity was also associated with pexpression level. Our results revealed no antagonistic effect of high doses of FA/VB12 on MTA efficacy in cancer cells grown in nutrient medium. Furthermore, these data may partially explain why supplementation of FA and VB12 resulted in better survival in MTA-treated patients.
Keywords
Funding Information
- National Science Council (NSC-100-2320-B-040-005)
This publication has 29 references indexed in Scilit:
- Development of an ion-pairing reversed-phase liquid chromatography method using a double detection analysis (UV and evaporative light scattering detection) to monitor the stability of Alimta®-pemetrexed preparations: Identification and quantification of l-glutamic acid as a potential degradation productJournal of Pharmaceutical and Biomedical Analysis, 2011
- Survey and Biological Insights of Pemetrexed-Related Therapeutic Improvement in Mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma CohortJournal of Thoracic Oncology, 2009
- Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) GroupAnnals of Oncology, 2009
- Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II studyAnnals of Oncology, 2009
- Therapy of metastatic bladder carcinomaAnnals of Oncology, 2007
- A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancerBritish Journal of Cancer, 2007
- Molecular basis of antifolate resistanceCancer and Metastasis Reviews, 2007
- A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal CancerOncology, 2007
- Understanding and Managing Methotrexate NephrotoxicityThe Oncologist, 2006
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948